<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625751</url>
  </required_header>
  <id_info>
    <org_study_id>H-20031245</org_study_id>
    <nct_id>NCT04625751</nct_id>
  </id_info>
  <brief_title>Neurovascular Coupling and Autonomic Neuropathy in Type 2 Diabetes</brief_title>
  <official_title>Unravelling the Association Between Neurovascular Uncoupling and Autonomic Neuropathy in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartwig R. Siebner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Research Centre for Magnetic Resonance</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is a growing global health care challenge. Diabetes patients may also suffer from&#xD;
      cardiovascular autonomic neuropathy (CAN) which may affect cerebral perfusion. The main&#xD;
      purpose of this project is to investigate the association between CAN and disturbances in the&#xD;
      neurovascular coupling in type 2 diabetes patients. Moreover, the purpose is also to&#xD;
      investigate coherence between CAN and the enteric nervous system. Finally, this project aims&#xD;
      at delineating microstructural changes in the brain tissues as a consequence of CAN.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurovascular coupling</measure>
    <time_frame>1 hour</time_frame>
    <description>Ratio between oxygen delivery/oxygen consumption by MRI during visual and hypercapnic stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrovascular reactivity</measure>
    <time_frame>1 hour</time_frame>
    <description>Change in CBF between normocapnia and hypercapnia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural differences in brain tissue</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Regional splanchnic blood flow increase in response to meal test</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood levels of gastrointestinal hormones and markers of metabolism following meal test</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Cardiovascular Autonomic Neuropathy</condition>
  <arm_group>
    <arm_group_label>T2DM +CAN</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM -CAN</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CO2-enriched air</intervention_name>
    <description>To assess cardiovascular reactivity</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>T2DM +CAN</arm_group_label>
    <arm_group_label>T2DM -CAN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Meal response test</intervention_name>
    <description>Meal response test to assess changes in splanchnic blood flow.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>T2DM +CAN</arm_group_label>
    <arm_group_label>T2DM -CAN</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes and cardiovascular autonomic neuropathy. Patients with type 2&#xD;
        diabetes but no cardiovascular autonomic neuropathy Healthy controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of type 2 diabetes (Patients)&#xD;
&#xD;
          -  Age between 50-70 years (All)&#xD;
&#xD;
          -  Presence of CAN as diagnosed by cardiovascular reflex tests with two or three&#xD;
             pathological results (Patients with CAN only)&#xD;
&#xD;
          -  Exclusion of CAN as diagnosed by cardiovascular reflex tests with no pathological&#xD;
             results (Patients without CAN and HC only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants receiving treatment with direct effects on noradrenergic or cholinergic&#xD;
             signaling (for example beta-blockers, tricyclic antidepressants, SSRI's) (All)&#xD;
&#xD;
          -  Acute infections (All)&#xD;
&#xD;
          -  Thyroid disease (All)&#xD;
&#xD;
          -  Substance or alcohol abuse (All)&#xD;
&#xD;
          -  Atrial fibrillation or flutter (All)&#xD;
&#xD;
          -  Respiratory failure (All)&#xD;
&#xD;
          -  Participants in active laser treatment for retinopathy, will be excluded from the&#xD;
             Valsalva test (Patients)&#xD;
&#xD;
          -  Non-diabetic causes of neuropathy including a medical history of vitamin B12&#xD;
             deficiency, folic acid deficiency, rheumatoid arthritics, amyloidosis, HIV, syphilis,&#xD;
             Borreliosis, drug induced neuropathy and neuropathy caused by toxins (All)&#xD;
&#xD;
          -  Claustrophobia (All)&#xD;
&#xD;
          -  Implanted pacemakers or remaining pacemaker electrodes (All)&#xD;
&#xD;
          -  Previous heart or brain surgery with use of metal clips (All)&#xD;
&#xD;
          -  Any form of non-MR-compatible implants&#xD;
&#xD;
          -  Non-compliance with the study protocol as judged by the investigators (All)&#xD;
&#xD;
          -  Concurrent participation in an intervention study (Patients)&#xD;
&#xD;
          -  Participants who by judgments of the investigator, is incapable of participating (All)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hartwig R. Siebner, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Research Centre for Magnetic Resonance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mads CJ Barloese, MD</last_name>
    <phone>+45386220188</phone>
    <email>mbar0087@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Hansen, MD, PhD</last_name>
      <email>christian.stevns.hansen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Danish Research Centre for Magnetic Resonance</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mads Barloese, MD, PhD</last_name>
      <phone>+4538622188</phone>
      <email>mbar0087@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Christian Bauer</last_name>
      <email>christian.bauer@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Danish Research Centre for Magnetic Resonance</investigator_affiliation>
    <investigator_full_name>Hartwig R. Siebner</investigator_full_name>
    <investigator_title>Professor, DMSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

